In particular, data from ORAL SURVEILLANCE in patients diagnosed with rheumatoid arthritis aged over 50 years with cardiovascular risk factors indicated a higher incidence of pulmonary embolism and venous thrombosis among patients treated with tofacitinib compared those treated with anti-tumor necrosis factor (TNF) agents [8]. The gene discussed is TNF; the disease is pulmonary embolism.